Estrogens and Estrogen Receptor Modulators in Cancer Research and Therapy (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 1376
Special Issue Editor
Interests: estrogen receptors; ER and GPER-1 signaling; breast and ovarian cancer; non-coding RNAs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This collection is the second edition of the Special Issue “Estrogens and Estrogen Receptor Modulators in Cancer Research and Therapy” (https://www.mdpi.com/journal/cancers/special_issues/estrogen_cancer).
Estrogens affect oncogenesis and tumor progression in a variety of cancer entities such as prostate cancer, colorectal cancer, breast cancer, and gynecological tumors of the endometrium and ovary. Three primary mediators of estrogen actions are currently known: estrogen receptor (ER)α, ERβ, and G-protein coupled estrogen receptor 1 (GPER1). ERα triggers tumor growth in breast cancer (and other cancer types) and is thereby an established therapy target in this cancer entity. The function of Erβ in cancer is less understood, particularly due to former problems regarding antibody specificity, and it is suggested to act as a partial ERα antagonist and a tumor suppressor in various cancer types such as breast and prostate cancer, although further research on the function of ERβ in these and other cancer entities is required. Another level of complexity was added by the realization that the ESR1 and ESR2 genes code for multiple splice variants, which are partially translated into proteins with altered functions. Increasing evidence suggests that GPER1 contributes to endocrine therapy resistance in breast cancer while also playing a complex role in a number of other cancers, including melanoma. Further efforts are needed to elucidate the pleiotropic function of GPER1 in cancer. Additionally, recent evidence suggests that estrogens not only act on tumor cells but also on the function of multiple cells of the tumor microenvironment, including fibroblasts, immune cells, and adipocytes, which can greatly affect carcinogenesis. This is another important mechanism of estrogen effects in cancer, which needs further investigation.
In this Special Issue of Cancers, we aim to stimulate discussions on these topics by bringing together expert opinions from across the field. We welcome submissions (original research papers and comprehensive reviews) that cover any relevant topic, such as estrogen signaling and function in less-studied cancer types, the function of receptor splice variants in cancer, the role of ER and GPER1 in any cancer entity, the effect of ER modulators and their combinations on cancer cells, the significance of the interaction between estrogen- and growth factor signaling, or the effect of estrogens on the efficacy of targeted cancer therapy drugs.
Prof. Dr. Oliver Treeck
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- estrogen-dependent cancer
- estrogens
- estrogen receptors
- estrogen receptor splice variants
- estrogen receptor modulators
- estrogen signaling
- cancer therapy
